Liposomes can be prepared with different size, charge and fluidity. A large variety of antitumor drugs can be encapsulated. The long term objective of the project is to design liposomes as tumor-specific carriers for the antitumor drugs. In the last funding period we have succeeded in covalently coupling to liposomes monoclonal antibodies specific for cell surface antigens and demonstrated target-specific cytotoxicity of drugs encapsulated in the immunoliposome. We have also shown that immunoliposomes are endocytosed by the target cell. A new type of immunoliposome has been designed which becomes highly fusion competent when exposed to acidic pH in the range of 4 to 6. We have demonstrated that these pH-sensitive immunoliposomes can efficiently deliver their contents into the cytoplasm of the target cells. We propose to verify the mechanism of delivery is via an acid induced fusion of the liposome membrane and the membrane of the endosome, in a manner similar to the infection pathway of the Influenza and Semliki Forest Viruses. Immunoliposomes containing fusion-active peptides will be prepared for effective liposome fusion either at the endosome level (acidic pH) or at the plasma membrane level (neutral pH). Immunoliposomes which release the contents upon binding to the target cells will also be prepared. The biophysical principle of the design is based on the lateral phase separation of the antibody and the formation of the hexagonal phase by the unsaturated phosphatidylethanolamine. The role of antibody density of the immunoliposomes on the target-specific cell binding will be examined. Liposomes containing two types of antibody for different antigens on the same tumor cell will be used for increased target specificity. Killing of the tumor cells by cytotoxic drugs encapsulated in various types of immunoliposomes will be examined in vitro. In vivo cytotoxicity will be evaluated with lymphoma cells grown in the nude mice. Finally, a brain tumor model will be established in dogs for intrathecal administration of liposomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA024553-07
Application #
3166474
Study Section
Molecular Cytology Study Section (CTY)
Project Start
1979-01-01
Project End
1988-07-31
Budget Start
1985-09-01
Budget End
1986-07-31
Support Year
7
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Tennessee Knoxville
Department
Type
Schools of Arts and Sciences
DUNS #
City
Knoxville
State
TN
Country
United States
Zip Code
37996
Huang, Xiao-Li; Fan, Zheng; Zheng, Lian et al. (2003) Priming of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cell responses by dendritic cells loaded with HIV-1 proteins. J Infect Dis 187:315-9
Whitmore, M; Li, S; Huang, L (1999) LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 6:1867-75
Savva, M; Duda, E; Huang, L (1999) A genetically modified recombinant tumor necrosis factor-alpha conjugated to the distal terminals of liposomal surface grafted polyethyleneglycol chains. Int J Pharm 184:45-51
Brisson, M; He, Y; Li, S et al. (1999) A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes. Gene Ther 6:263-70
He, Y K; Lui, V W; Baar, J et al. (1998) Potentiation of E7 antisense RNA-induced antitumor immunity by co-delivery of IL-12 gene in HPV16 DNA-positive mouse tumor. Gene Ther 5:1462-71
Li, S; Deshmukh, H M; Huang, L (1998) Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm Res 15:1540-5
Shurin, G; Shanks, N; Nelson, L et al. (1997) Hypothalamic-pituitary-adrenal activation by the bacterial superantigen staphylococcal enterotoxin B: role of macrophages and T cells. Neuroendocrinology 65:18-28
Bedu-Addo, F K; Tang, P; Xu, Y et al. (1996) Interaction of polyethyleneglycol-phospholipid conjugates with cholesterol-phosphatidylcholine mixtures: sterically stabilized liposome formulations. Pharm Res 13:718-24
Mori, A; Wu, S P; Han, I et al. (1996) In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Cancer Chemother Pharmacol 37:435-44
Bedu-Addo, F K; Tang, P; Xu, Y et al. (1996) Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: implications in liposomal drug delivery. Pharm Res 13:710-7

Showing the most recent 10 out of 90 publications